Vertex Pharmaceuticals (VRTX) Net Cash Flow (2009 - 2026)

Vertex Pharmaceuticals has reported Net Cash Flow for 18 years, with the latest figure at $457.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 453.08% year-over-year to $457.4 million; the trailing twelve-month figure through Mar 2026 stood at $799.4 million (up 117.81% YoY), and the FY2025 full-year result was $424.7 million, up 107.38% from the prior year.
• Net Cash Flow for Q1 2026 stood at $457.4 million, up from $132.7 million in the prior quarter.
• The five-year high for Net Cash Flow was $1.3 billion in Q4 2022, with the low at -$4.6 billion in Q2 2024.
• Average Net Cash Flow over 5 years is -$76.5 million, with a median of $239.4 million recorded in 2025.
• Year-over-year, Net Cash Flow jumped 558.1% in 2022 and slumped 639.74% in 2024.
• Tracing VRTX's Net Cash Flow over 5 years: stood at $1.3 billion in 2022, then slumped by 159.63% to -$771.7 million in 2023, then grew by 18.54% to -$628.6 million in 2024, then jumped by 121.11% to $132.7 million in 2025, then surged by 244.69% to $457.4 million in 2026.
• The last three Net Cash Flow figures came in at $457.4 million (Q1 2026), $132.7 million (Q4 2025), and -$30.1 million (Q3 2025), per Business Quant data.

Peer Comparison